Sclerostin serum levels correlate positively with bone mineral density and microarchitecture in haemodialysis patients

Nephrology Dialysis Transplantation

Volumn 27, Issue 1, 2012, Pages 226-230

  Cejka, Daniel ^a   Jäger Lansky, Agnes ^a   Kieweg, Heidi ^a   Weber, Michael ^a   Bieglmayer, Christian ^a   Haider, Dominik G ^a   Diarra, Danielle ^a   Patsch, Janina M ^a   Kainberger, Franz ^a   Bohle, Barbara ^a   Haas, Martin ^a  

^a MEDICAL UNIVERSITY OF VIENNA   (Austria)

Author keywords

dialysis; Dickkopf 1; HR pQCT; renal osteodystrophy; sclerostin; Wnt signaling

Indexed keywords

25 HYDROXYERGOCALCIFEROL; ALKALINE PHOSPHATASE BONE ISOENZYME; BIOLOGICAL MARKER; CALCITRIOL; CALCIUM; CARBOXY TERMINAL TELOPEPTIDE; DICKKOPF 1 PROTEIN; INTACT PARATHYROID HORMONE; OSTEOCALCIN; PARATHYROID HORMONE; PHOSPHATE; SCLEROSTIN; UNCLASSIFIED DRUG; VITAMIN D;

ADULT; ARTICLE; BONE DENSITY; BONE MICROARCHITECTURE; BONE STRUCTURE; BONE TURNOVER; CONTROLLED STUDY; DISEASE ASSOCIATION; DUAL ENERGY X RAY ABSORPTIOMETRY; FEMALE; FEMUR NECK; HEMODIALYSIS PATIENT; HIGH RESOLUTION COMPUTER TOMOGRAPHY; HUMAN; LUMBAR SPINE; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; PROTEIN BLOOD LEVEL; RADIUS; SEX DIFFERENCE; TIBIA; TRABECULAR BONE;

ABSORPTIOMETRY, PHOTON; BIOLOGICAL MARKERS; BONE AND BONES; BONE DENSITY; BONE MORPHOGENETIC PROTEINS; CASE-CONTROL STUDIES; CROSS-SECTIONAL STUDIES; FEMALE; GENETIC MARKERS; HUMANS; MALE; MIDDLE AGED; PARATHYROID HORMONE; PROGNOSIS; RENAL DIALYSIS;

EID: 84856639090     PISSN: 09310509     EISSN: 14602385     Source Type: Journal    
DOI: 10.1093/ndt/gfr270     Document Type: Article

References (31)

1. Krishnan V, Bryant HU, Macdougald OA. Regulation of bone mass by Wnt signaling. J Clin Invest 2006; 116: 1202-1209
2. Brunkow ME, Gardner JC, Van NJ et al. Bone dysplasia sclerosteosis results from loss of the SOST gene product, a novel cystine knot-containing protein. Am J Hum Genet 2001; 68: 577-589 (Pubitemid 32202753)
3. Balemans W, Patel N, Ebeling M et al. Identification of a 52 kb deletion downstream of the SOST gene in patients with van Buchem disease. J Med Genet 2002; 39: 91-97 (Pubitemid 34146376)
4. Li X, Ominsky MS, Niu QT et al. Targeted deletion of the sclerostin gene in mice results in increased bone formation and bone strength. J Bone Miner Res 2008; 23: 860-869 (Pubitemid 351768804)
5. Ominsky MS, Vlasseros F, Jolette J et al. Two doses of sclerostin antibody in cynomolgus monkeys increases bone formation, bone mineral density, and bone strength. J Bone Miner Res 2010; 25: 948-959
6. Padhi D, Jang G, Stouch B et al. Single-dose, placebo-controlled, randomized study of AMG 785, a sclerostin monoclonal antibody. J Bone Miner Res 2011; 26: 19-26
7. Bellido T, Ali AA, Gubrij I et al. Chronic elevation of parathyroid hormone in mice reduces expression of sclerostin by osteocytes: a novel mechanism for hormonal control of osteoblastogenesis. Endocrinology 2005; 146: 4577-4583 (Pubitemid 41446595)
8. O'Brien CA, Plotkin LI, Galli C et al. Control of bone mass and remodeling by PTH receptor signaling in osteocytes. PLoS ONE 2008; 3: e2942
9. Mirza FS, Padhi ID, Raisz LG et al. Serum sclerostin levels negatively correlate with parathyroid hormone levels and free estrogen index in postmenopausal women. J Clin Endocrinol Metab 2010; 95: 1991-1997
10. Mukhopadhyay M, Shtrom S, Rodriguez-Esteban C et al. Dickkopf1 is required for embryonic head induction and limb morphogenesis in the mouse. Developmental Cell 2001; 1: 423-434 (Pubitemid 33586091)
11. Morvan F, Boulukos K, Clement-Lacroix P et al. Deletion of a single allele of the Dkk1 gene leads to an increase in bone formation and bone mass. J Bone Miner Res 2006; 21: 934-945 (Pubitemid 43788000)
12. Tian E, Zhan F, Walker R et al. The role of the Wnt-signaling antagonist DKK1 in the development of osteolytic lesions in multiple myeloma. N Engl J Med 2003; 349: 2483-2494 (Pubitemid 38010074)
13. Garnero P, Tabassi NC, Voorzanger-Rousselot N. Circulating dickkopf-1 and radiological progression in patients with early rheumatoid arthritis treated with etanercept. J Rheumatol 2008; 35: 2313-2315
14. London GM, Marty C, Marchais SJ et al. Arterial calcifications and bone histomorphometry in end-stage renal disease. J Am Soc Nephrol 2004; 15: 1943-1951 (Pubitemid 38822076)
15. Mittalhenkle A, Gillen DL, Stehman-Breen CO. Increased risk of mortality associated with hip fracture in the dialysis population. Am J Kidney Dis 2004; 44: 672-679 (Pubitemid 39237611)
16. Slatopolsky E, Finch J, Clay P et al. A novel mechanism for skeletal resistance in uremia. Kidney Int 2000; 58: 753-761 (Pubitemid 30620025)
17. Cejka D, Herberth J, Branscum AJ et al. Sclerostin and Dickkopf-1 in renal osteodystrophy. Clin J Am Soc Nephrol 2011; 6: 877-882
18. Boutroy S, Bouxsein ML, Munoz F et al. In vivo assessment of trabecular bone microarchitecture by high-resolution peripheral quantitative computed tomography. J Clin Endocrinol Metab 2005; 90: 6508-6515 (Pubitemid 41759306)
19. Laib A, Hauselmann HJ, Ruegsegger P. In vivo high resolution 3D-QCT of the human forearm. Technol Health Care 1998; 6: 329-337 (Pubitemid 29090456)
20. Laib A, Hildebrand T, Hauselmann HJ et al. Ridge number density: a new parameter for in vivo bone structure analysis. Bone 1997; 21: 541-546 (Pubitemid 28029698)
21. Robling AG, Niziolek PJ, Baldridge LA et al. Mechanical stimulation of bone in vivo reduces osteocyte expression of Sost/sclerostin. J Biol Chem 2008; 283: 5866-5875
22. Gaudio A, Pennisi P, Bratengeier C et al. Increased sclerostin serum levels associated with bone formation and resorption markers in patients with immobilization-induced bone loss. J Clin Endocrinol Metab 2010; 95: 2248-2253
23. Coen G, Bonucci E, Ballanti P et al. PTH 1-84 and PTH "7-84" in the noninvasive diagnosis of renal bone disease. Am J Kidney Dis 2002; 40: 348-354 (Pubitemid 34827653)
24. Kulkarni NH, Halladay DL, Miles RR et al. Effects of parathyroid hormone on Wnt signaling pathway in bone. J Cell Biochem 2005; 95: 1178-1190 (Pubitemid 41420125)
25. Li X, Ominsky MS, Warmington KS et al. Sclerostin antibody treatment increases bone formation, bone mass, and bone strength in a rat model of postmenopausal osteoporosis*. J Bone Miner Res 2009; 24: 578-588
26. Winkler DG, Sutherland MK, Geoghegan JC et al. Osteocyte control of bone formation via sclerostin, a novel BMP antagonist. EMBO J 2003; 22: 6267-6276 (Pubitemid 37522584)
27. Reppe S, Refvem H, Gautvik VT et al. Eight genes are highly associated with BMD variation in postmenopausal Caucasian women. Bone 2010; 46: 604-612
28. Patsch JM, Kohler T, Berzlanovich A et al. Trabecular bone micro-structure and local gene expression in iliac crest biopsies of men with idiopathic osteoporosis. J Bone Miner Res 2011. doi: 10.1002/jbmr.344
29. Mödder UI, Hoey KA, Amin S et al. Relation of age, gender, and bone mass to circulating sclerostin levels in women and men. J Bone Miner Res 2011; 26: 373-379
30. Shen C, Buck AK, Liu X et al. Gene silencing by adenovirus-delivered siRNA. FEBS Lett 2003; 539: 111-114 (Pubitemid 36351297)
31. Romero G, Sneddon WB, Yang Y et al. Parathyroid hormone receptor directly interacts with dishevelled to regulate beta-Catenin signaling and osteoclastogenesis. J Biol Chem 2010; 285: 14756-14763